Merck plans to double manufacturing capacity for its antiviral pill to treat Covid-19 next year as governments scramble to procure a treatment that a late-stage trial showed cuts hospitalisation and death rates in half.
默克(Merck)计划明年将其治疗新冠的抗病毒药物的产能提高一倍。目前各国政府正竞相采购这种药物，一项后期临床试验显示它将住院率和死亡率降低了一半。
您已阅读5%（293字），剩余95%（5372字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。